ES2422173T3 - Composiciones que contienen aecuorina y procedimientos de uso de las mismas - Google Patents

Composiciones que contienen aecuorina y procedimientos de uso de las mismas

Info

Publication number
ES2422173T3
ES2422173T3 ES05766584T ES05766584T ES2422173T3 ES 2422173 T3 ES2422173 T3 ES 2422173T3 ES 05766584 T ES05766584 T ES 05766584T ES 05766584 T ES05766584 T ES 05766584T ES 2422173 T3 ES2422173 T3 ES 2422173T3
Authority
ES
Spain
Prior art keywords
aecuorin
procedures
compositions containing
compositions
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05766584T
Other languages
English (en)
Inventor
Mark Y Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quincy Bioscience LLC
Original Assignee
Quincy Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience LLC filed Critical Quincy Bioscience LLC
Application granted granted Critical
Publication of ES2422173T3 publication Critical patent/ES2422173T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Aecuorina para su uso como medicamento.
ES05766584T 2004-06-21 2005-06-21 Composiciones que contienen aecuorina y procedimientos de uso de las mismas Active ES2422173T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
PCT/US2005/021770 WO2006010004A2 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
ES2422173T3 true ES2422173T3 (es) 2013-09-09

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05766584T Active ES2422173T3 (es) 2004-06-21 2005-06-21 Composiciones que contienen aecuorina y procedimientos de uso de las mismas

Country Status (21)

Country Link
US (3) US20060229243A1 (es)
EP (2) EP2545934B1 (es)
JP (1) JP4971150B2 (es)
KR (1) KR101213555B1 (es)
CN (1) CN1997383B (es)
AU (1) AU2005265266B2 (es)
BR (1) BRPI0512392B1 (es)
CA (1) CA2571542C (es)
CY (1) CY1114307T1 (es)
DK (1) DK1768691T3 (es)
ES (1) ES2422173T3 (es)
HK (1) HK1109576A1 (es)
IL (1) IL180195A (es)
MX (1) MXPA06015037A (es)
NZ (1) NZ552274A (es)
PL (1) PL1768691T3 (es)
PT (1) PT1768691E (es)
SG (1) SG153848A1 (es)
SI (1) SI1768691T1 (es)
WO (1) WO2006010004A2 (es)
ZA (1) ZA200610688B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
JP5508294B2 (ja) * 2008-03-11 2014-05-28 クインシー バイオサイエンス，リミティド ライアビリティ カンパニー アポイクオリン含有組成物及びその使用方法
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
CA2822594A1 (en) * 2010-12-24 2012-06-28 Otsuka Pharmaceutical Co., Ltd. Bioassay method for detecting physiologically active substance
WO2013074798A1 (en) * 2011-11-15 2013-05-23 Quincy Bioscience, Llc Apoaequorin for reducing neuronal injury due to ischemia
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
WO2001096361A1 (en) * 2000-06-12 2001-12-20 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Also Published As

Publication number Publication date
NZ552274A (en) 2010-06-25
EP2545934B1 (en) 2014-12-10
IL180195A (en) 2014-03-31
WO2006010004A2 (en) 2006-01-26
KR101213555B1 (ko) 2012-12-18
EP2545934A1 (en) 2013-01-16
PT1768691E (pt) 2013-06-20
PL1768691T3 (pl) 2013-09-30
MXPA06015037A (es) 2007-07-11
AU2005265266A1 (en) 2006-01-26
ZA200610688B (en) 2007-12-27
KR20070070154A (ko) 2007-07-03
AU2005265266B2 (en) 2011-05-12
CN1997383A (zh) 2007-07-11
BRPI0512392A (pt) 2008-03-11
CY1114307T1 (el) 2016-08-31
US20100152117A1 (en) 2010-06-17
EP1768691A4 (en) 2010-08-04
SG153848A1 (en) 2009-07-29
IL180195A0 (en) 2007-06-03
EP1768691B1 (en) 2013-05-22
CA2571542C (en) 2014-08-19
JP4971150B2 (ja) 2012-07-11
US20060229243A1 (en) 2006-10-12
WO2006010004A3 (en) 2007-03-08
HK1109576A1 (en) 2008-06-13
JP2008503581A (ja) 2008-02-07
EP1768691A2 (en) 2007-04-04
US20080287350A1 (en) 2008-11-20
DK1768691T3 (da) 2013-07-01
US7671015B2 (en) 2010-03-02
SI1768691T1 (sl) 2013-07-31
CN1997383B (zh) 2011-01-05
BRPI0512392B1 (pt) 2022-12-13
CA2571542A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
CR7828A (es) Oxialquilamidas de quinolina, isoquinolina y quinazolina y su uso como fungicidas
UY30304A1 (es) Moduladores de mglur5 i
CR9786A (es) Compuestos de bencimidazol-tiofeno
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
UY31038A1 (es) Compuestos
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
UY30308A1 (es) Moduladores de mglur5 v
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
NI200900071A (es) Compuestos de pirozolina y su uso y composiciones farmacéuticas. pc 33496a.
CR9930A (es) Compuestos
UY32659A (es) Pirazinilpirazoles
ES2422173T3 (es) Composiciones que contienen aecuorina y procedimientos de uso de las mismas
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
UY30307A1 (es) Moduladores de mglur5 vi
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
UY30306A1 (es) Moduladores de mglur5 iii